Amendments to the Claims:

Please amend claims 7 and 8 as shown in the listing of claims.

Please cancel claims 1-6, 14-19, and 20- 30 without prejudice.

The current listing of claims replaces all prior listings of claims in the application.

Listing of Claims:

1-6. (Canceled).

7. (Currently Amended) A method for detecting an enteroviral infection in a subject's heart, the method comprising in vitro immunological detection of a dystrophin cleavage product in blood or cardiovascular tissue obtained from the subject, wherein the dystrophin cleavage product is produced by enteroviral protease 2A cleavage of the rod domain of dystrophin, wherein the detection is performed in an ~~assay~~ immunoassay using a detectably labeled dystrophin eptitope-specific antibody or Fab fragment thereof, wherein binding of the antibody indicates that a dystrophin cleavage product resulting from an enteroviral infection is present in the blood or cardiovascular tissue assayed.

8. (Currently Amended) The method according to claim 7, wherein the dystrophin epitope-specific antibody is specific to a the dystrophin cleavage product produced by enteroviral protease 2A cleavage of the rod domain of dystrophin.

9. (Original) The method according to claim 8, wherein the rod domain encompasses a hinge segment of dystrophin.

10. (Original) The method according to claim 8, wherein the dystrophin cleavage product is the 588 cleavage product.

11. (Original) The method according to claim 9, wherein the dystrophin cleavage product is the 2434 cleavage product.

12. (Original) The method according to claim 7, wherein the enteroviral infection is a Coxsackievirus infection.

13. (Original) The method according to claim 7, wherein the detection is performed on blood from the subject at least 12 hours following a suspected infection.

14-30. (Canceled).